CYP3A4 and B-cell chronic lymphocytic leukemia: We intend to address interindividual variability in the efficacy and safety of CLL patients on ibrutinib treatment by quantifying plasma ibrutinib levels and determining CYP3A polymorphisms that reduce the functionality of the enzyme.